bmjmedicine

(Check for updates

► Additional supplemental

material is published online

only. To view, please visit the

journal online (http://dx.doi. org/10.1136/bmjmed-2022-

¹Unit of Cardiovascular and

Nutritional Epidemiology,

Institute of Environmental

Stockholm, Sweden ²Department of Surgical

Uppsala, Sweden ³School of Psychological

Bristol, UK

Medicine, Karolinska Institutet,

Sciences, Uppsala University,

Science, University of Bristol,

⁴Faculty of Epidemiology and Population Health, London

School of Hygiene and Tropical

Integrative Epidemiology Unit,

University of Bristol, Bristol, UK

⁶Department of Epidemiology

Public Health, Imperial College

and Biostatistics. School of

London, London, UK

⁷Chief Scientific Advisor

Copenhagen, Denmark

Office, Research and Early

Development, Novo Nordisk,

Correspondence to: Dr Susanna

C Larsson, Karolinska Institutet,

Stockholm, 171 77, Sweden;

susanna.larsson@ki.se

Cite this as: BMIMED

2023:2. doi:10.1136/

bmjmed-2022-000335

Received: 1 August 2022

Accepted: 18 January 2023

Medicine London LIK

⁵Medical Research Council

000335).

Appraisal of the causal effect of plasma caffeine on adiposity, type 2 diabetes, and cardiovascular disease: two sample mendelian randomisation study

Susanna C Larsson (D), ^{1,2} Benjamin Woolf, ^{3,4,5} Dipender Gill (D) ^{6,7}

ABSTRACT

OBJECTIVE To investigate the potential causal effects of long term plasma caffeine concentrations on adiposity, type 2 diabetes, and major cardiovascular diseases.

DESIGN Two sample mendelian randomisation study.

SETTING Genome-wide association study summary data for associations of two single nucleotide polymorphisms associated with plasma caffeine at the genome-wide significance threshold (rs2472297 near the CYP1A2 gene and rs4410790 near the AHR gene) and their association with the outcomes. **PARTICIPANTS** Primarily individuals of European ancestry participating in cohorts contributing to genome-wide association study consortia. MAIN OUTCOME MEASURES Outcomes studied were body mass index, whole body fat mass, whole body fat-free mass, type 2 diabetes, ischaemic heart disease, atrial fibrillation, heart failure, and stroke. **RESULTS** Higher genetically predicted plasma caffeine concentrations were associated with lower body mass index (beta -0.08 standard deviation (SD) (95% confidence interval -0.10 to -0.06), where 1 SD equals about 4.8 kg/m² in body mass index, for every standard deviation increase in plasma caffeine) and whole body fat mass (beta -0.06 SD (-0.08 to -0.04), 1 SD equals about 9.5 kg; P<0.001) but not fat-free mass (beta -0.01 SD (-0.02 to -0.00), 1 SD equals about 11.5 kg; P=0.17). Higher genetically predicted plasma caffeine concentrations were associated with a lower risk of type 2 diabetes in two consortia (FinnGen and DIAMANTE), with a combined odds ratio of 0.81

WHAT IS ALREADY KNOWN ON THIS TOPIC

- \Rightarrow Small, short term trials have shown that caffeine intake results in weight and fat mass reduction, but the long term effects of caffeine intake is unknown
- ⇒ Consumption of coffee, a rich source of caffeine, is observationally associated with a lower risk of type 2 diabetes and cardiovascular disease

WHAT THIS STUDY ADDS

- ⇒ Genetically predicted, lifelong, higher plasma caffeine concentrations were associated with lower body mass index and fat mass, as well as a lower risk of type 2 diabetes
- ⇒ Approximately half of the effect of caffeine on type 2 diabetes was estimated to be mediated through body mass index reduction

HOW MIGHT THIS STUDY AFFECT RESEARCH, PRACTICE, OR POLICY

⇒ Long term clinical studies investigating the effect of caffeine intake on fat mass and type 2 diabetes risk are warranted ((95% confidence interval 0.74 to 0.89); P<0.001). Approximately half (43%; 95% confidence interval 30% to 61%) of the effect of caffeine on type 2 diabetes was estimated to be mediated through body mass index reduction. No strong associations were reported between genetically predicted plasma caffeine concentrations and a risk of any of the studied cardiovascular diseases.

CONCLUSIONS Higher plasma caffeine concentrations might reduce adiposity and risk of type 2 diabetes. Further clinical study is warranted to investigate the translational potential of these findings towards reducing the burden of metabolic disease.

Introduction

Caffeine (1,3,7-trimethylxanthine) is a widely consumed psychoactive substance. The main sources of caffeine globally are from coffee, tea, and soda drinks.^{1–3} Considering the extensive intake of caffeine worldwide,^{1–3} even its small metabolic effects could have important health implications.

Caffeine has thermogenic effects^{4–9} and has been implicated in reducing weight, body mass index (BMI), and fat mass in short term randomised controlled trials.^{10–12} Hence, a high caffeine intake might lower the risk of diseases related to adiposity, such as type 2 diabetes and cardiovascular disease. Evidence from observational studies supports an inverse association between coffee consumption and risk of type 2 diabetes, with all identified studies reporting a statistically significant or nonsignificant inverse association.¹³ In a dose-response meta-analysis, the risk of type 2 diabetes decreased by 7% for each cup per day increase of caffeinated coffee (an average cup contains around 70-150 mg caffeine) and by 6% for each cup per day increase of decaffeinated coffee.¹³ Observational findings on the association between coffee consumption and risk of ischaemic heart disease,^{3 14} stroke,^{14 15} and cardiovascular disease mortality¹⁶⁻¹⁸ are less consistent with both inverse and positive associations reported by different studies. However, observational studies cannot reliably infer causality because coffee consumption is associated with other factors (eg, other dietary and lifestyle factors, ethnic group, and socioeconomic status),19 potentially resulting in confounded associations. Furthermore, the specific effect of caffeine on the risk of cardiometabolic diseases might be difficult to disentangle

BMJ

from the other compounds included in caffeinated drinks and foods.¹³ Randomised controlled trials on caffeine consumption and chronic diseases are costly and difficult to implement. To our knowledge, no randomised controlled trials have been published on the effect of caffeine on risk of developing type 2 diabetes and cardiovascular disease. Nevertheless, a randomised controlled trial of the effect of coffee consumption on insulin sensitivity and other biological risk factors for type 2 diabetes in 126 adults who were overweight and had no sensitivity to insulin showed that consumption of four cups per day of caffeinated coffee for 24 weeks had no effect on insulin sensitivity or biological mediators of insulin resistance. This study did show an association with a reduction in fat mass and urinary creatinine concentration.12

The metabolism of caffeine occurs largely in the liver by the cytochrome P450 isoform 1A2 (CYP1A2).²⁰ Genetic variations near genes *CYP1A2* and *AHR* (which regulates the expression of *CYP1A2*) are associated with plasma concentrations of caffeine.²⁰ Individuals who carry genetic variants that are associated with slower caffeine metabolism consume, on average, less coffee but have higher plasma caffeine concentrations.²⁰ This finding probably relates to individuals with a slow metabolism of caffeine consequently consuming less coffee and caffeine than people who have a fast caffeine metabolism, to reach or retain the concentrations of caffeine required for the desired psychostimulant effects.²⁰

We leveraged genetic variants in caffeine metabolism through the mendelian randomisation framework to investigate the causal effects of long term exposure to higher plasma caffeine concentrations on adiposity, type 2 diabetes, and major cardiovascular diseases. The purpose of mendelian randomisation analysis is to improve causal inference by use of genetic variants that are reliably and strongly associated with the exposure as unbiased proxy indicators. As genetic variants are fixed at conception, individuals with genetic variants that are associated with higher plasma caffeine concentrations will, on average, be exposed to higher caffeine concentrations throughout their life compared with people with variants associated with lower plasma caffeine.


Methods

Study design and assumptions

We used a two sample mendelian randomisation design with summary genetic data obtained from genome-wide association studies. An overview of the study design is shown in figure 1. The genetic variants that we used as instrumental variables in mendelian randomisation analysis were expected to fulfill the three assumptions: strongly associated with the exposure (relevance assumption); not associated with potential confounders (independence assumption); and affect the outcome via the exposure and not via any other pathway (exclusion restriction assumption).

Data sources

Single nucleotide polymorphisms (SNPs) that are associated with plasma caffeine were obtained from a genome-wide association meta-analysis of 9876 individuals of European ancestry from six population based studies.²⁰ That study identified genomewide significant associations of SNPs near CYP1A2 and AHR loci with plasma caffeine concentrations.²⁰ The SNPs within each locus were in linkage disequilibrium (r^2 ranging from 0.21 to 0.96 in European populations), therefore, we selected the strongest signal at each locus, that is, rs2472297 at CYP1A2 (P=1.0×10-20) and rs4410790 at AHR $(P=1.8\times10-13)$, as instrumental variables in the mendelian randomisation analyses. Estimates of the associations of the caffeine SNPs were obtained for BMI (whole body fat mass) from the GIANT consortium²¹ and for body composition (whole body fatfree mass) from the Medical Research Council's Integrative Epidemiology Unit. These estimates were extracted from the MR-Base platform.²² The corresponding summary genetic data for type 2 diabetes and cardiovascular disease subtypes were obtained from the FinnGen (R7 data),²³ DIAMANTE (European),²⁴ CARDIoGRAMplusC4D (including UK Biobank data),²⁵ HERMES,²⁶ and MEGASTROKE (restricted to individuals of European ancestry)²⁷ consortia. Summary genetic data for atrial fibrillation were obtained from a meta-analysis of six studies.²⁸ Details of the used data sources are presented in the online supplemental table 1. All summary statistics



used in the mendelian randomisation analyses are shown in the online supplemental table 2.

Statistical analysis

The mendelian randomisation estimate for the association of plasma caffeine with each outcome was computed by dividing the estimate of the SNP and outcome association (beta coefficient or log odds ratio) by the estimate of the SNP and caffeine association (ie, Wald ratio). This calculation used a standard deviation (SD) unit, which was estimated from the standardised (z) scores representing the change in plasma caffeine per effect allele from the caffeine genome-wide association study.²⁰ The mendelian randomisation estimates for the two caffeine associated SNPs were then combined according to the inverse-variance weighted method. We combined the results for two studies using a random-effects meta-analysis (DerSimonian and Laird method), and calculated heterogeneity between studies using Cochran's Q test. Results were deemed statistically significant at the Bonferroni corrected threshold of P<0.006 (P=0.05, eight studied outcomes). An association with a P value between 0.006 and 0.05 was considered suggestive evidence of an association.

As a follow-up analysis, we further conducted a two step network mendelian randomisation mediation analysis to explore the extent to which any effect of caffeine on type 2 diabetes might be mediated through BMI.²⁹ The proportion mediated was calculated as the estimated effect of caffeine consumption on BMI multiplied by the estimated effect of BMI on type 2 diabetes. When estimating the association of genetically predicted BMI with type 2 diabetes, we selected genome-wide significant SNPs from the GIANT genome-wide association study on BMI (n=483) to be instrumental variables, as described previously. For the type 2 diabetes genetic association estimates, we performed a random-effects metaanalysis of FinnGen and DIAMANTE. In addition to the inverse variance weighted meta-analysis of the Wald ratios specific to the SNPs, we implemented three estimators that were deemed to be robust for pleiotropy (ie, when a genetic variant associates with more than one phenotype) as a sensitivity analysis: MR-Egger, weighted median, and weighted mode.³⁰ The standard error of the mediated effect was then estimated by use of bootstrap simulations with 100 000 iterations.³¹

Most widely employedstatistical sensitivity analyses that use mendelian randomisation methods to detect and adjust for pleiotropy cannot be conducted with only two instrumental variables. To assess potential pleiotropy of the SNPs associated with caffeine, we instead performed a phenome-wide association analysis in the MR-Base platform (lookup on 1 August 2022).²² Stata and R software were used to analyse the data and to create the forest plot figure.

Patient and public involvement

We did not engage patients or members of the public when designing this study, interpreting the results, or drafting the manuscript. They were also not involved in the dissemination plans of this study and we have no plans to disseminate the results to research participants and public communities.

Results

Characteristics of the studies used for the two sample mendelian randomisation analyses are shown in online supplemental table 1. All but one study encompassed participants of European ancestries only.²⁵ Genetically predicted higher plasma concentrations of caffeine were associated with lower BMI (beta -0.08 SD (95% confidence interval -0.10 to -0.06), where 1 SD equals about 4.8 kg/m², for every SD increase in plasma caffeine; P<0.001) and whole body fat mass (beta -0.06 SD (-0.08 to -0.04), 1 SD equals about 9.5 kg; P<0.001) but had a nonsignificant association with fat-free mass (beta -0.01 SD (-0.02 to -0.00), 1 SD equals about 11.5 kg; P=0.17). Additionally, genetically predicted higher plasma caffeine concentrations were associated with a lower risk of type 2 diabetes in both the FinnGen (odds ratio 0.77 (95% confidence interval 0.70 to 0.85) per SD increase in plasma caffeine; P<0.001) and the DIAMANTE consortia (0.84 (0.78 to 0.91); P<0.001); the combined odds ratio of type 2 diabetes per SD increase in plasma caffeine was 0.81 ((0.74 to 0.89); P<0.001) with no evidence of heterogeneity between the two studies (Q=2.39, P=0.12) (figure 2). Both SNPs were strongly associated with lower BMI, fat mass, and type 2 diabetes risk (all P<0.005) (online supplemental table 2). No strong association was observed between genetically predicted plasma caffeine with risk of ischaemic heart disease, atrial fibrillation, heart failure, or stroke, and no heterogeneity was noted among studies (Q<0.48, P>0.49 (figure 2)).

When performing mediation analysis to investigate the proportion of the effect of caffeine on type 2 diabetes liability that was mediated via BMI reduction, we detected heterogeneity in the inversevariance weighted mendelian randomisation estimate (P<0.001, see online supplemental table 3 for full results). We, therefore, used the weighted median estimator for the mediation analysis because this estimator is both reasonably efficient and robust to pleiotropy. Our two step mediation analysis reported that the odds of type 2 diabetes per SD increase in plasma caffeine related to mediation through BMI was 0.91 (95% confidence interval 0.90 to 0.94). This finding suggested that 43% (30% to 61%) of the protective effect of plasma caffeine on type 2 diabetes was mediated through BMI (figure 3).

In the phenome-wide association analysis performed in the MR-Base platform, 39 763 phenotype associations were available for the *CYP19A1*

Outcome/ consortium	Cases	Non-cases	Odds ratio (95% Cl)	Odds ratio (95% Cl)	P value
Type 2 diabetes					
FinnGen	44 266	256 217		0.77 (0.70 to 0.85)	<0.001
DIAMANTE	74 124	824 006		0.84 (0.78 to 0.91)	<0.001
Combined	118 390	1 080 223		0.81 (0.74 to 0.89)	<0.001
Ischaemic heart disea	ses				
FinnGen	49 030	260 124		0.92 (0.83 to 1.01)	0.07
CARDIoGRAMplusC4D	122 733	424 528		0.95 (0.79 to 1.16)	0.64
Combined	171 763	684 652		0.92 (0.85 to 1.01)	0.07
Atrial fibrillation					
FinnGen	34 748	156 457		0.93 (0.82 to 1.06)	0.27
AFGen	60 620	970 216		0.99 (0.88 to 1.12)	0.89
Combined	95 368	1 126 673		0.96 (0.88 to 1.05)	0.39
Heart failure					
FinnGen	19 676	272 371		1.03 (0.90 to 1.18)	0.65
HERMES	47 309	930 014		1.01 (0.92 to 1.11)	0.86
Combined	66 985	1 202 385	-	1.02 (0.94 to 1.10)	0.69
Stroke					
FinnGen	20 0 29	280 171		1.00 (0.88 to 1.14)	0.98
MEGASTROKE	40 585	406 111		0.97 (0.87 to 1.09)	0.64
Combined	60 614	686 282		0.99 (0.91 to 1.07)	0.73
		0	.7 1.0	1.3	

Figure 2 | Genetically predicted higher plasma caffeine concentration and risk of type 2 diabetes and major cardiovascular diseases. The odds ratios with their corresponding 95% confidence intervals (CIs) are scaled per one standard deviation increase in plasma caffeine concentration. Cochran's *Q* test statistic for heterogeneity between study specific estimates: Q=2.39 (P=0.12) for type 2 diabetes, Q=0.13 (P=0.72) for ischaemic heart disease, Q=0.48 (P=0.49) for atrial fibrillation, Q=0.08 (P=0.78) for heart failure, and Q=0.11 (P=0.74) for stroke

SNP and 40 553 were available for *AHR*. The alleles that increase plasma caffeine of the two SNPs were, in addition to lower coffee and tea consumption and lower BMI, associated with higher water and cereal intake and with renal biomarkers, including creatinine, urea, albumin, phosphate, sodium, and cystatin C at the genome-wide significance threshold (online supplemental tables 4 and 5). The SNP in the *CYP1A2* locus was additionally associated with higher peak expiratory flow, platelet distribution width and volume, diastolic blood pressure, and impedance of arm and lower leg fat percentage. The SNP in the *AHR* locus was further associated with higher concentrations of potassium in urine and

liver biomarkers bilirubin and alkaline phosphatase, improved lipid profile, lower glycated haemoglobin concentrations, and lower concentrations of the protein sex hormone binding globulin, which was adjusted for BMI.

Discussion

Principal findings

In this mendelian randomisation investigation aimed at deciphering the possible long term causal effects of increased plasma caffeine on cardiometabolic outcomes, genetically predicted higher plasma caffeine concentrations were associated with lower BMI and whole body fat mass. Furthermore,




Figure 3 | Causal directed acyclic graph showing the total effect of plasma caffeine on type 2 diabetes risk and the effect mediated by body mass index. The presented mendelian randomisation effect estimates with their corresponding 95% confidence intervals (shown in parenthesis) are scaled per one standard deviation increase in plasma caffeine concentration. BMI=body mass index

genetically predicted higher plasma caffeine concentrations were associated with a lower risk of type 2 diabetes. Approximately half of the effect of caffeine on type 2 diabetes liability was estimated to be mediated through BMI reduction. No evidence suggested an association of genetically predicted higher plasma caffeine concentrations with ischaemic heart disease, atrial fibrillation, heart failure, and stroke.

Comparison with other studies

The association between plasma caffeine concentrations and type 2 diabetes risk has been scarcely investigated. Nonetheless, the association of caffeinated or total coffee consumption with the risk of type 2 diabetes has been examined in many observational studies,¹³ which collectively support an inverse dose-response relation. Our mendelian randomisation finding suggests that caffeine might, at least in part, explain the inverse association between coffee consumption and risk of type 2 diabetes. In contrast to observational findings, no clear association has been reported between genetically predicted coffee consumption and type 2 diabetes in mendelian randomisation analyses.^{3 32 33} A one sample mendelian randomisation analysis based on the Copenhagen General Population Study showed no association of a allele score for coffee intake, consisting of SNPs near CYP1A2 and AHR genes, with risk of type 2 diabetes.³² Two sample mendelian randomisation studies based on data from the Diabetes Genetics Replication And Meta-analysis (DIAGRAM) consortium suggested a positive association between risk of type 2 diabetes and consumption of coffee (by 12 SNPs) and caffeine (from coffee, tea, or both; by 35 SNPs).^{3 33} Our findings for plasma caffeine might superficially seem inconsistent and contradictory to previous mendelian randomisation analyses of coffee and caffeine consumption. However, this discrepancy is expected because the genetic variants in the two genomic regions that are associated with higher plasma caffeine concentrations, due to potentially slower metabolism of caffeine, are also associated with lower coffee and caffeine consumption,²⁰ which was also observed in our phenome-wide association analysis. In addition to different exposures (plasma caffeine concentrations v coffee or caffeine intake), the genetic method in our study was confined to SNPs located in genes encoding enzymes with an established role in caffeine metabolism, either directly via the CYP1A2 enzyme or indirectly (AHR) by the regulation of CYP1A2 expression. Studies based on a larger set of instrumental variables^{3 33} included several SNPs in genes with a less clear or unknown role in predicting higher coffee and caffeine consumption,³⁴ which can increase the risk of bias from pleiotropy.

Data for plasma caffeine and risk of cardiovascular disease are scarce, but several observational and mendelian randomisation studies have reported disease incidence and mortality. Evidence from observational studies indicates that, compared with no coffee consumption, moderate consumption of coffee (three to five cups/day) is associated with lower risk of ischaemic heart disease^{14 16} and stroke.^{14 15} Observational studies further suggest that moderate coffee consumption might be associated with lower risk of heart failure^{35 36} but not with atrial fibrillation.³⁷ Previous mendelian randomisation studies have not found any significant association between genetically predicted coffee consumption and total cardiovascular disease^{38 39} or specific cardiovascular diseases, including ischaemic heart disease and stroke.^{3 38 40 41} Given that the association between coffee consumption and cardiovascular disease risk seems to be non-linear, our mendelian randomisation study on plasma caffeine and previous mendelian randomisation studies on coffee consumption might have been unable to detect significant associations. Another possibility is that the observed associations in these observational studies are driven by residual confounding or reverse causation. Additionally, our mendelian randomisation analyses that investigated cardiovascular outcomes might have been underpowered due to low phenotypic variance explained by the used instrumental variables. Impaired glycaemic control increases cardiovascular risk, thereby suggesting that a protective effect of higher caffeine concentrations on diabetes liability would also reduce cardiovascular risk. The 95% confidence interval for the cardiovascular outcomes suggested that any possible protective effect of plasma caffeine concentrations on ischaemic heart disease is unlikely to be larger than 15% or more harmful than a 1% increase, likewise, for atrial fibrillation, a maximum of a 12% protective effect and 5% increase in harm.

results on coffee consumption and cardiovascular

As in previous mendelian randomisation studies,³³ we found a strong association between genetically predicted BMI and type 2 diabetes risk. The magnitude of the association was somewhat stronger in our mendelian randomisation analysis than in previous mendelian randomisation studies,³³ which might be related to different instruments used for BMI and different data sources for type 2 diabetes.

Biological mechanisms

In terms of mechanisms, caffeine might reduce BMI and fat mass by increasing thermogenesis^{4–9} and fat oxidation.^{42–44} The effect of caffeine on energy expenditure is dose-dependent and the thermogenic response is positively correlated with the response in plasma caffeine.⁹ A daily intake of 100 mg of caffeine has been estimated to increase energy expenditure by approximately 100 kcal (418.4 kJ) per day,⁸ which could consequently lower the risk of developing obesity. The elevated energy expenditure attributable to caffeine consumption might be mediated through increased thermogenesis of brown adipose

tissue.⁴⁵ An alternative mechanism whereby higher caffeine concentrations reduce adiposity is through enhanced satiety¹³ and suppressed energy intake.⁴⁶ The observed association between genetically predicted higher plasma caffeine concentrations with lower type 2 diabetes risk is partly mediated by reduced overall body fat, which is strongly causally associated with this disease.^{33 47} Our mendelian randomisation mediation analyses support this hypothesis.

The genetic alleles that are associated with higher plasma caffeine concentrations are also associated with lower coffee and tea consumption. Thus, an alternative mechanism is that individuals who carry those alleles have a lower risk of type 2 diabetes. compared with those with other sets of alleles, because of lower exposure to any other substances in coffee (eg, diterpenes) or tea that increase the risk of type 2 diabetes.⁴⁸ In this regard, the plasma caffeine raising allele for the SNP in the AHR locus was associated with lower concentrations of triglycerides, low density lipoprotein cholesterol, and the protein sex hormone binding globulin, adjusted for BMI, as well as higher concentrations of bilirubin and alkaline phosphatase. The association with triglycerides and cholesterol might be related to lipid raising diterpenes (ie, cafestol and kahweol) present in unfiltered coffee.⁴⁸ Coffee and caffeine consumption has been reported to be associated with sex hormone binding globulin⁴⁹ as well as certain biomarkers of liver function and liver cancer.⁵⁰

Strengths and limitations of the study

An important strength of this study is the mendelian randomisation design, which minimises bias due to reverse causation because genetic variants are fixed at conception and cannot be changed by disease status. The study design also reduces potential effects of confounding factors because the genetic variants associated with the exposure under study are generally not associated with environmental exposures and other self-adopted behaviours, except for caffeine containing beverage consumption in this mendelian randomisation study. Another important strength is that the genetic instrument for plasma caffeine comprised SNPs in genes with a known role in caffeine metabolism, thereby reducing risk of bias due to pleiotropy. Additionally, both SNPs were strongly associated with type 2 diabetes risk in two independent large scale consortia, strengthening the evidence of causality. A limitation is that possible non-linear relations between plasma caffeine and the outcomes could not be explored within the current two sample mendelian randomisation design. Another shortcoming is that we could not conduct sensitivity analyses using commonly employed mendelian randomisation methods for detecting possible pleiotropy, such as MR-Egger regression and MR-PRESSO, because those approaches require

at least three or more instrumental variables. Nevertheless, we conducted phenome-wide association analysis and found that only a few of the associated phenotypes (coffee and tea consumption and renal biomarkers) had a stronger association with the specific outcome phenotypes under study than plasma caffeine concentration did, despite the much larger sample sizes of these studies (about 7 to 80 times larger than in the plasma caffeine study). This finding implies that the associated phenotypes are probably downstream consequences of higher plasma caffeine, rather than biasing pleiotropic effects. Another limitation is that although our mendelian randomisation study provides evidence of a causal effect of plasma caffeine on reducing adiposity and type 2 diabetes risk, the extent of the association does not inform on the potential impact of any clinical or public health intervention. The use of only two SNPs for caffeine exposure reduced the power of the mendelian randomisation analyses. Additionally, because genetic predictors of plasma caffeine concentrations in people who are not of European ethnicity are not established and our data sources comprised European individuals only, our findings might not be generalisable to populations of non-European ethnicity.

Conclusion

This mendelian randomisation study found evidence to support causal associations of higher plasma caffeine concentrations with lower adiposity and risk of type 2 diabetes. Randomised controlled trials are warranted to assess whether non-caloric caffeine containing beverages might play a role in reducing the risk of obesity and type 2 diabetes.

Twitter Susanna C Larsson @LarssonSC

Acknowledgements We thank the study participants and investigators of the FinnGen, DIAMANTE, CARDIoGRAMplusC4D, AFGen, HERMES, and MEGASTROKE consortia.

Contributors SCL contributed to the conception of the study and wrote the first draft of the manuscript. SCL and BW performed statistical analysis. All authors contributed to the design of the study and edited the manuscript for intellectual content. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. Transparency: The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Funding This study was supported by the Swedish Research Council for Health, Working Life and Welfare (Forte, 2018-00123), Swedish Heart Lung Foundation (Hjärt-Lungfonden, 20210351), and Swedish Research Council (Vetenskapsrådet, 2019-00977). DG was supported by the British Heart Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College.

Competing interests Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/ disclosure-of-interest/ and declare: no support from any organisation for the submitted work; DG is employed part-time by Novo Nordisk; the other authors declare no conflicts of interest.

Ethics approval This study involves human participants and was approved by This mendelian randomisation study bases on summary statistics data was approved by the Swedish Ethical Review Authority (no. 2019-02793). Participants in included studies had provided informed consent. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. All data analysed during the current study are available in online supplemental table 2.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs

Susanna C Larsson http://orcid.org/0000-0003-0118-0341 Dipender Gill http://orcid.org/0000-0001-7312-7078

REFERENCES

- Frary CD, Johnson RK, Wang MQ. Food sources and intakes of caffeine in the diets of persons in the United States. J Am Diet Assoc 2005;105:110–3. 10.1016/j.jada.2004.10.027
- 2 Reyes CM, Cornelis MC. Caffeine in the diet: country-level consumption and guidelines. Nutrients 2018;10:1772. 10.3390/ nu10111772
- 3 Said MA, van de Vegte YJ, Verweij N, *et al.* Associations of observational and genetically determined caffeine intake with coronary artery disease and diabetes mellitus. J Am Heart Assoc 2020;9:e016808. 10.1161/JAHA.120.016808
- 4 Astrup A, Toubro S, Cannon S, et al. Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a doubleblind, placebo-controlled study. Metabolism 1991;40:323–9. 10.1016/0026-0495(91)90117-f
- 5 Arciero PJ, Bougopoulos CL, Nindl BC, et al. Influence of age on the thermic response to caffeine in women. Metabolism 2000;49:101–7. 10.1016/S0026-0495(00)90888-6
- 6 Arciero PJ, Gardner AW, Calles-Escandon J, *et al.* Effects of caffeine ingestion on Ne kinetics, fat oxidation, and energy expenditure in younger and older men. Am J Physiol 1995;268(6 Pt 1):E1192–8. 10.1152/ajpendo.1995.268.6.E1192
- 7 Astrup A, Toubro S. Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man. Int J Obes Relat Metab Disord 1993;17 Suppl 1:S41–3.
- 8 Dulloo AG, Geissler CA, Horton T, *et al.* Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. Am J Clin Nutr 1989;49:44–50. 10.1093/ajcn/49.1.44
- 9 Astrup A, Toubro S, Cannon S, et al. Caffeine: a double-blind, placebo-controlled study of its thermogenic, metabolic, and cardiovascular effects in healthy volunteers. Am J Clin Nutr 1990;51:759–67. 10.1093/ajcn/51.5.759
- 10 Tabrizi R, Saneei P, Lankarani KB, et al. The effects of caffeine intake on weight loss: a systematic review and dos-response meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr 2019;59:2688–96. 10.1080/10408398.2018.1507996
- Moura de Araújo MF, Gueiros Gaspar MW, Saraiva Veras V, et al. Consumption of caffeinated and decaffeinated coffee enriched with cocoa and fructo-oligosaccharides among non-diabetic persons: double blind randomized clinical trial. J Food Biochem 2022;46:e14081. 10.1111/jfbc.14081
- 12 Alperet DJ, Rebello SA, Khoo EY-H, *et al.* The effect of coffee consumption on insulin sensitivity and other biological risk factors for type 2 diabetes: a randomized placebo-controlled trial. Am J Clin Nutr 2020;111:448–58. 10.1093/ajcn/nqz306

- 13 Carlström M, Larsson SC. Coffee consumption and reduced risk of developing type 2 diabetes. Nutr Rev 2018;76:395–417. 10.1093/ nutrit/nuy014
- 14 Ding M, Bhupathiraju SN, Satija A, et al. Long-term coffee consumption and risk of cardiovascular disease: a systematic review and a dose-response meta-analysis of prospective cohort studies. Circulation 2014;129:643–59. 10.1161/ CIRCULATIONAHA.113.005925
- 15 Chan L, Hong CT, Bai CH. Coffee consumption and the risk of cerebrovascular disease: a meta-analysis of prospective cohort studies. BMC Neurol 2021;21:380. 10.1186/s12883-021-02411-5
- 16 Crippa A, Discacciati A, Larsson SC, et al. Coffee consumption and mortality from all causes, cardiovascular disease, and cancer: a dose-response meta-analysis. Am J Epidemiol 2014;180:763–75. 10.1093/aje/kwu194
- Park S-Y, Freedman ND, Haiman CA, et al. Association of coffee consumption with total and cause-specific mortality among nonwhite populations. Ann Intern Med 2017;167:228–35. 10.7326/ M16-2472
- 18 Gunter MJ, Murphy N, Cross AJ, et al. Coffee drinking and mortality in 10 European countries: a multinational cohort study. Ann Intern Med 2017;167:236–47. 10.7326/M16-2945
- 19 Rehm CD, Ratliff JC, Riedt CS, et al. Coffee consumption among adults in the United States by demographic variables and purchase location: analyses of NHANES 2011-2016 data. Nutrients 2020;12:22463. 10.3390/nu12082463
- 20 Cornelis MC, Kacprowski T, Menni C, et al. Genome-wide association study of caffeine metabolites provides new insights to caffeine metabolism and dietary caffeine-consumption behavior. Hum Mol Genet 2016;25:5472–82. 10.1093/hmg/ddw334
- 21 Yengo L, Sidorenko J, Kemper KE, et al. Meta-analysis of genomewide association studies for height and body mass index in ~700000 individuals of european ancestry. Hum Mol Genet 2018;27:3641-9. 10.1093/hmg/ddy271
- 22 Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife 2018;7:e34408. 10.7554/eLife.34408
- 23 FinnGen study. Data freeze 8 results and summary statistics. Available: https://finngen.gitbook.io/documentation/ [Accessed 14 Dec 2022].
- 24 Mahajan A, Taliun D, Thurner M, *et al.* Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet 2018;50:1505–13. 10.1038/s41588-018-0241-6
- 25 van der Harst P, Verweij N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. Circ Res 2018;122:433–43. 10.1161/ CIRCRESAHA.117.312086
- 26 Shah S, Henry A, Roselli C, *et al.* Genome-wide association and mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nat Commun 2020;11:163. 10.1038/ s41467-019-13690-5
- 27 Malik R, Chauhan G, Traylor M, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat Genet 2018;50:524–37. 10.1038/s41588-018-0058-3
- 28 Nielsen JB, Thorolfsdottir RB, Fritsche LG, et al. Biobank-driven genomic discovery yields new insight into atrial fibrillation biology. Nat Genet 2018;50:1234–9. 10.1038/s41588-018-0171-3
- 29 Burgess S, Daniel RM, Butterworth AS, et al. Network Mendelian randomization: using genetic variants as instrumental variables to investigate mediation in causal pathways. Int J Epidemiol 2015;44:484–95. 10.1093/ije/dyu176
- 30 Slob EAW, Burgess S. A comparison of robust Mendelian randomization methods using summary data. Genet Epidemiol 2020;44:313–29. 10.1002/gepi.22295
- 31 Woolf B, Zagkos L, Gill D. TwoStepCisMR: a novel method and R package for attenuating bias in cis-mendelian randomization analyses. Genes (Basel) 2022;13:1541. 10.3390/genes13091541
- 32 Nordestgaard AT, Thomsen M, Nordestgaard BG. Coffee intake and risk of obesity, metabolic syndrome and type 2 diabetes: a Mendelian randomization study. Int J Epidemiol 2015;44:551–65. 10.1093/ije/dyv083
- 33 Yuan S, Larsson SC. An atlas on risk factors for type 2 diabetes: a wide-angled Mendelian randomisation study. Diabetologia 2020;63:2359–71. 10.1007/S00125-020-05253-x
- 34 Cornelis MC, Munafo MR. Mendelian randomization studies of coffee and caffeine consumption. Nutrients 2018;10:1343. 10:3390/ nu10101343
- 35 Mostofsky E, Rice MS, Levitan EB, *et al.* Habitual coffee consumption and risk of heart failure: a dose-response meta-analysis. Circ Heart Fail 2012;5:401–5. 10.1161/CIRCHEARTFAILURE.112.967299
- 36 Bodar V, Chen J, Sesso HD, *et al.* Coffee consumption and risk of heart failure in the physicians' health study. Clin Nutr ESPEN 2020;40:133–7. 10.1016/j.clnesp.2020.09.216

- 37 Larsson SC, Drca N, Jensen-Urstad M, et al. Coffee consumption is not associated with increased risk of atrial fibrillation: results from two prospective cohorts and a meta-analysis. BMC Med 2015;13:207. 10.1186/S12916-015-0447-8
- 38 Nordestgaard AT. Causal relationship from coffee consumption to diseases and mortality: a review of observational and Mendelian randomization studies including cardiometabolic diseases, cancer, gallstones and other diseases. Eur J Nutr 2022;61:573–87. 10.1007/ S00394-021-02650-9
- 39 Nordestgaard AT, Nordestgaard BG. Coffee intake, cardiovascular disease and all-cause mortality: observational and Mendelian randomization analyses in 95 000-223 000 individuals. Int J Epidemiol 2016;45:1938–52. 10.1093/ije/dyw325
- 40 Karhunen V, Bakker MK, Ruigrok YM, et al. Modifiable risk factors for intracranial aneurysm and aneurysmal subarachnoid hemorrhage: a mendelian randomization study. J Am Heart Assoc 2021;10:e022277. 10.1161/JAHA.121.022277
- 41 Yuan S, Carter P, Mason AM, *et al.* Coffee consumption and cardiovascular diseases: a Mendelian randomization study. Nutrients 2021;13:2218. 10.3390/nu13072218
- 42 Collado-Mateo D, Lavín-Pérez AM, Merellano-Navarro E, et al. Effect of acute caffeine intake on the fat oxidation rate during exercise: a systematic review and meta-analysis. Nutrients 2020;12:3603. 10.3390/nu12123603
- 43 Ramírez-Maldonado M, Jurado-Fasoli L, Del Coso J, et al. Caffeine increases maximal fat oxidation during a graded exercise test: is there a diurnal variation? J Int Soc Sports Nutr 2021;18:5. 10.1186/ s12970-020-00400-6

- 44 Ruiz-Moreno C, Gutiérrez-Hellín J, Amaro-Gahete FJ, *et al.* Caffeine increases whole-body fat oxidation during 1 H of cycling at fatmax. Eur J Nutr 2021;60:2077–85. 10.1007/S00394-020-02393-z
- 45 Van Schaik L, Kettle C, Green R, *et al.* Effects of caffeine on brown adipose tissue thermogenesis and metabolic homeostasis: a review. Front Neurosci 2021;15:621356. 10.3389/ fnins.2021.621356
- 46 Schubert MM, Irwin C, Seay RF, et al. Caffeine, coffee, and appetite control: a review. Int J Food Sci Nutr 2017;68:901–12. 10.1080/09637486.2017.1320537
- 47 Larsson SC, Burgess S. Causal role of high body mass index in multiple chronic diseases: a systematic review and meta-analysis of Mendelian randomization studies. BMC Med 2021;19:320. 10.1186/ s12916-021-02188-x
- 48 Cai L, Ma D, Zhang Y, *et al.* The effect of coffee consumption on serum lipids: a meta-analysis of randomized controlled trials. Eur J Clin Nutr 2012;66:872–7. 10.1038/ejcn.2012.68
- 49 Pihan-Le Bars F, Gusto G, Boutron-Ruault M-C, et al. Cross-Sectional association of coffee and caffeine consumption with sex hormonebinding globulin in healthy nondiabetic women. Clin Endocrinol (Oxf) 2017;87:475–83. 10.1111/cen.13411
- 50 Larsson SC, Wolk A. Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology 2007;132:1740-5. 10.1053/j. gastro.2007.03.044

► Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi.org/10.1136/ bmjmed-2022-000335).